Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs
The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.
Cure Today1d
Breaking Down the FDA Labeling Update of Xeloda and 5-FU in Cancer Care
The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...
'The great modern Champions League rivalry?' - Guardiola speaks before Real clash
All the latest news as Pep Guardiola speaks to the media before Manchester City's Champions League play-off match against ...
STAT11d
Pharmalittle: We’re reading about FDA OK for Vertex non-opioid pain drug, vaccine advisory committee, and more
Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...
Wyoming News12d
Bright stars to fill the sky in February
You’ll find several bright planets, stars and obvious constellations in the February evening sky. The most obvious ...
Reuters19d
US FDA drops web pages on improving clinical trial diversity
The FDA's Diversity Action Plan draft guidance to drug and medical device companies stems from the 2022 Food and Drug Omnibus Reform Act. It aims to significantly increase participation of ...
NBC News20d
Federal regulations paused, halting FDA's proposed ban on formaldehyde in hair products
Not all chemical hair relaxers include the chemical, but many include ingredients that can release formaldehyde when heated, the FDA said in 2024. Over the years, an increasing number of studies ...
Newsweek21d
FDA Approves Nasal Spray for Depression
However, it had to be used in conjunction with an oral medication. The FDA has now expanded its approval to include the standalone use of the nasal spray for adults with treatment-resistant major ...
Popular Science21d
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...
UPI21d
FDA approves Spravato, first monotherapy nasal spray to treat depression
Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.
Putnam Daily Voice21d
Nasal Spray Treating Major Depression Receives FDA Approval For Standalone Use
The FDA granted approval to Spravato (esketamine) as the first monotherapy for adults with treatment-resistant depression, J&J said in a news release on Tuesday, Jan. 21. The decision came after a ...